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TOPIRAMATE FOR THE TREATMENT OF
JUVENILE MYOCLONIC EPILEPSY
Patrícia da Silva Sousa, Gerardo Maria de Araújo Filho,
Eliana Garzon, Américo C. Sakamoto, Elza Márcia T. Yacubian
ABSTRACT - O b j e c t i v e: The aim of this study was to evaluate the efficacy and tolerability of topiramate ( T P M )
in juvenile myoclonic epilepsy (JME). M e t h o d: We assessed seizure control and adverse effects of TPM in
22 patients (18 females) aged 13 to 53 years. Ta rget TPM dosage was up to 200 mg/day. The patients were
subdivided into 3 groups: those treated with seizure control plus side effects (n=4); treated with non-con-
t rolled seizures (n=15) and with JME newly diagnosed (n=3). Results: Sixteen patients completed the first
year of the follow-up. Generalized tonic-clonic seizures were completely controlled in 10 (62.5%); more t h a n
50% of reduction in 4 (25.0%) and less than 50% in 2 (12.5%). Myoclonia were controlled in 11 (68.8%) a n d
persisted in 5 (31.2%) patients. Absence seizures were present in 5 (22.7%) of whom 2 (9.0%) showed more
than 50% of seizure reduction while 3 (13.6%) presented worsening. Discontinuations were due to inad-
equate seizure control and adverse events (N=4), low compliance and loss of follow-up (N=2) and subject
choice (N=1). C o n c l u s i o n: TPM showed to be an effective and well-tolerated drug in the treatment of
JME. Although frequently observed, TPM side effects were tolerable and the drug could be maintained in
the majority of patients.
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Tratamento da epilepsia mioclônica juvenil com topiramato
RESUMO - Objetivo: Avaliar a eficácia e tolerabilidade do topiramato (TPM) na epilepsia mioclônica juve-
nil (EMJ). Método: Avaliamos a resposta terapêutica e efeitos colaterais do TPM em 22 pacientes (18 mulh e-
res) com idades entre 13 e 53 anos. A dose alvo utilizada foi até 200 mg/dia. Os pacientes foram divididos
em 3 grupos no início do tratamento:  aqueles com controle das crises mas que apresentavam efeitos colate-
rais (n=4); com crises não controladas (n=15) e com EMJ recém diagnosticada (n=3). Resultados: D e z e s s e i s
pacientes completaram o primeiro ano de acompanhamento. Crises tônico-clonicas generalizadas foram c o m-
pletamente controladas em 10 (62,5%), tiveram redução maior de 50% em 4 (25,0%) e menor de 50% em
2 (12,5%). Mioclonias foram controladas em 11 (68,8%) e persistiram em 5 (31.2%) pacientes. As crises de
ausências, presentes em 5 (22,7%) pacientes, tiveram redução maior do que 50% em 2 (9,0%) e agrava-
mento em 3 (13,6%). A retirada do estudo foi devida principalmente ao controle inadequado das crises e
efeitos colaterais indesejáveis (n=4), pouca adesão e perda do seguimento (n=2) e escolha do paciente ( n = 1 ) .
Conclusão: TPM foi considerada droga eficaz e bem tolerada no tratamento da EMJ. Apesar de fre q ü e n-
temente observados, os efeitos colaterais do TPM foram toleráveis e a medicação pode ser mantida na
maioria dos pacientes. 
PALAVRAS-CHAVE: topiramato, tratamento, epilepsia mioclônica juvenil.
Va l p roate (VPA) has been considered the dru g
of choice in the treatment of juvenile myoclonic e p i-
lepsy (JME). Diff e rent series1 - 3 re p o rted good to e x-
cellent control of seizures in 70-85% of patients
with VPA monotherapy or polytherapy. VPA is ef-
fective in the three types of seizures, generalized
tonic-clonic seizures (GTCS), myoclonia and ab-
sences, which characterize this syndrome. Despite
its satisfactory eff i c a c y, side effects such as weight
gain, polycistic ovary and hormonal disturbance h a v e
led to other therapeutical strategies.
R e c e n t l y, topiramate (TPM), lamotrigine and
zonisamide have also been shown to be eff e c t i v e
in this syndro m e4 - 7. TPM may re p resent a therapeu-
tic alternative in JME since it has an equally bro a d
p rofile. In fact, some studies have demonstrated
the efficacy of TPM in generalized seizures, includ-
ing those of JME8. Others have suggested that des-
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pite the effectiveness of TPM in the control of G T C S ,
its efficacy in the control of absences and myoclo-
nic seizures is poorer4,6.
This is a prospective study for evaluation of eff i-
cacy and tolerability of TPM in a series of patients
with JME. 
METHOD
In this study we included 22 JME patients followed
up between March 1s t, 2003, and January 1s t, 2005 at H o s-
pital São Paulo Epilepsy Outpatient Clinic, Universidade
Federal de São Paulo. The Ethic Committee of the institu-
tion approved the protocol, and informed consent was
obtained from all participants. 
TPM was administered as a first drug or as a substitu-
ted drug in the treatment of the 22 patients (13-53 yr.;
mean 23.2). Eight patients were being treated with VPA
(500-2000 mg/day, in 2 of them associated with clonaze-
pam 3 and 10 mg/day), 4 with CBZ (600-1400 mg/day), 2
PB (100 mg/day), one with oxcarbazepine (600 m g / d a y ) ,
one with lamotrigine (25 mg/day). Six patients were not
being treated. These patients were divided into thre e
g roups. Groups 1 and 2 included patients already being
t reated with other AED and were constituted by: (a) pa-
tients with controlled seizures but presenting side eff e c t s
(n= 4); (b) patients already receiving AED but with non-
c o n t rolled seizures (n=15) and (c) patients with newly
diagnosed JME (n=3). TPM was titrated according to pa-
tients’ response over 12-14 weeks and maintained for a n
additional 32 weeks. Ta rget TPM dosage was reached w i t h
the increase of 25 mg each 15 days up to 200 mg/day.
The doses of the initial therapy were reduced 25% of
initial doses per week. The exit criteria were occurre n c e
of GTCS or intolerable side effects. The patients were
evaluated in the 2n d, 4t h, 6t h, 8t h and 12t h weeks and then
in the 6t h, 9t h and 12t h months as to therapeutic effect a n d
adverse events. Patients and family quantified the num-
ber of GTCS, myoclonia and absences per day in a diary.
Psychiatric evaluation was perf o rmed in all patients and
body mass index (BMI) was registered in each visit.
Statistical analysis – The small number of part i c i p a n t s
did not allow statistical comparison of TPM efficacy in
p reviously treated and untreated groups. The compari-
son of those who presented seizure control, those with
s e i z u res not controlled and discontinued groups after
TPM introduction was assessed by individual seizure type
response and re g i s t e red by frequency (%). TPM tolerabi-
lity data was evaluated. Schedule Clinical Interview for
DSM-IV (SCID I) was perf o rmed to measure depre s s i o n
and humor instability. BMI at the beginning and at the
end of follow-up was compared using paired t-test of
Student. We considered statistically significant p< 0.05.
RESULTS
E fficacy – Twenty-two patients (18 females) we-
re enrolled, 16 of whom completed the first year o f
the follow-up (Figure). The mean dosage among
study completers varied from 50 mg to 175 mg per
day (mean 106.25± 55.43 mg/day). Suppression or
reduction > 50% of the frequency of seizures oc-
c u rred in 15 patients (68.2%). Sixteen patients com-
Figure. Fluxogram of patien´s follow-up.
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pleted the first year of the follow-up. In re l a t i o n
to GTCS, present in 16 patients, there was comple-
te seizure control in 10 (62.5%), more than 50% o f
GTCS reduction in 4 (25.0%) while 2 (12.5%) pre-
sented less than 50%. Myoclonia also present in
16 patients, were controlled in 11 (68.8%) and per-
sisted in 5 (31.2%) patients. Absence seizures were
p resent in 5 (27.7%) patients of whom 2 (9.0%) s h o-
wed more than 50% of seizure reduction while 3
(13.6%) presented worsening of this seizure type.
The frequency of myoclonia and GTCS is showed i n
Graphics 1 and 2. Most of the patients with con-
t rolled seizures plus side effects and those newly
diagnosed had their seizures controlled. Among
those who persisted having seizures despite the
use of other AED before TPM introduction, myoclo-
nia were improved in 46.6%, maintained the same
f requency in 20% and showed aggravation in
33.3%, while GTCS were improved in 60% and ag-
gravated in 40%.
Tolerability – The most prevalent side effect was
weight loss. At the enrollment, 11 (50%) of the
patients were over-weight (BMI > 25 kg/m2) while
Graphic 1. Evolution of myoclonia after topiramate according to group studied.
Graphic 2. Evolution of generalized tonic-clonic seizures after TPM according to group studied .
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7 (31.8%) were obese (BMI > 30 kg/m2). All over-
weight patients lost weight, 4 (36.4%) lost > 10%
of weight, 6 (54.5%) lost 5-10% while 1 (9.1%) lost
< 5%. Among those obese, 4 (57%) lost >10%. At
the moment of this evaluation, the mean absolute
variation of weight from the beginning to the end
of the follow up was - 5.49±1.35 kg (p=0.001 pai-
red T test) and the mean variation of BMI was -
2.13±0.51 (p=0.001 paired t test). 
The other side effects (Graphic 3) were re p re-
sented by thirst/dry mouth (81.8%), pare s t h e s i a s
(68.2%), appetite decrease (40.9%), somnolence
(31.8%), humor instability (27.3%), facial ru b o r
(22.8%), headache/memory difficulty (18.2%), de-
p ression/language problems/attention diff i c u l-
ty/dizziness (13.7%), dry eyes/ abdominal pain/ up-
per re s p i r a t o ry infection (9.0%). Paresthesias and
d ry mouth were more common during the titrat i o n
phase and tended to vanish after three months of
t h e r a p y. These side effects were tolerable and the
d rug could be maintained in the majority of pa-
t i e n t s . D e p ression, language problems and atten-
tion difficulty were observed in 3 patients who w e-
re on TPM > 100 mg. Humor instability was re g i s t e-
red in 6 patients who were on TPM 50-75 mg. The-
se symptoms persisted with maintenance of the
dosages; three of these patients had some bene-
fit of fluoxetine 20 mg/day.
Discontinuations were either due to inadequate
s e i z u re control and adverse events (N=4) or low
compliance and loss of follow-up (N=2) and sub-
ject choice (N=1). 
DISCUSSION
TPM has proven to be effective in treatment of
generalized epilepsy9. In patients with JME, it was
initially shown that TPM was effective in cases re-
fractory to other AED10, and later its efficacy was
demonstrated in patients with recent onset epilep-
sy and intolerable side effects of other AED4,5,8.
In a previous study, Rosenfeld et al.4 e v a l u a t e d
the efficacy of TPM in 15 adults with JME. Fourt e e n
of these patients had not achieved seizure contro l
with VPA and/or presented excessive weight gain
after institution of VPA therapy (5 subjects). TPM
in an average dose of 663 mg/day improved s e i z u re
f requency in 11 patients, maintained control in t w o
Graphic 3. Most common adverse events during all treatment.
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and led to worsening in two. In the series of Prasad
et al.5, TPM used in a minimum effective dose of
230 mg in monotherapy and 250 mg in polythera-
py was considered to be an alternative to VPA .
Tolerability to TPM was lower than to VPA, which
the authors attributed to excessively rapid titra-
tion of the drug; in this series, one of the 19 pa-
tients showed worsening of the seizures. Levisohn
et al.6 c o m p a red the efficacy of TPM vs. VPA in re-
cently diagnosed JME patients. Twelve of 19 pa-
tients randomized to TPM concluded the study, a n d
so did 7 out of the 9 patients in the VPA gro u p .
The average dose of TPM in the patients who con-
cluded the study was 250 mg/day, in comparison
to 750 mg/day of VPA.
In our series, TPM was administered in a lower
dose (50 to 175 mg per day) than that of pre v i o u s
studies. This is a tendency in the most recent series
p resented that have shown minimization of side
e ffects with maintained efficacy with low dose. In
a series of drug naive older patients with recent-
ly diagnosed partial-onset seizures Ramsay et al.1 1
showed that 50 mg of TPM as monotherapy, was
similar to 200 mg. In the study of Edwards et al.12
TPM 100 mg/day was shown to be at least as eff e c-
tive as 600 mg/day of carbamazepine and 1250
mg/day of VPA in newly diagnosed generalized
and focal epilepsies. These results agreed with pre-
vious observations such as that of Kwan and Bro-
d i e1 3 who mentioned the necessity of low-to-mod-
erate dosages of AED in patients successfully tre a t-
ed with monotherapy. 
In our series, TPM reduced the seizure fre q u e n-
cy in approximately 2/3 of patients with JME in the
first year of follow-up, seeming more effective in
the control of GTCS and myoclonia than in absence
s e i z u res, despite the small number of patients with
this last seizure type. However, this study shows
that TPM may aggravate GTCS and myoclonia al-
though this was observed only in the group of pa-
tients with more re f r a c t o ry seizures. Side eff e c t s
w e re frequently observed in all patients. Some of
them, such as thirst and paresthesias, tended to d i-
minish with time, while other dose-dependent ef-
fects such as emotional instability, depression and
language difficulties were persistent in patients w i-
th dosage over 100 mg/day. 
Although frequently observed, TPM side eff e c t s
w e re tolerable and the drug could be maintained
in the majority of the patients.
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